GTS Securities’s Biogen BIIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
– Sell
-21,000
Closed -$4.07M – 1563
2024
Q3
$4.07M Buy
21,000
+2,700
+15% +$565K 0.01% 1026
2024
Q2
$4.24M Buy
18,300
+400
+2% +$86.9K 0.01% 969
2024
Q1
$3.86M Sell
17,900
-17,900
-50% -$4.19M 0.01% 1035
2023
Q4
$9.26M Sell
35,800
-7,500
-17% -$1.84M 0.02% 651
2023
Q3
$11.1M Buy
+43,300
New +$11.6M 0.02% 556

Other funds holding BIIB

GTS Securities's BIIB Position: Q3 2026 in Review

GTS Securities opened a new position in Biogen (BIIB) in Q3 2026: 1,497 shares worth $338K. The stake represents 0.01% of the portfolio and ranks #1160 among its holdings. This is a return to the name: GTS Securities previously reported a position in BIIB as recently as Q1 2026.

GTS Securities first reported a position in BIIB in Q2 2023 and has held it in 9 quarters since. The position peaked at $4.14M in Q4 2023. 1,048 funds tracked by Wall St. Rank hold BIIB as of Q3 2026.

  • GTS Securities held 1,497 shares of Biogen worth $338K as of Q3 2026.
  • Biogen was a new GTS Securities position in Q3 2026.
  • Biogen made up 0.01% of GTS Securities's portfolio in Q3 2026, its #1160 holding.
  • GTS Securities first reported a position in Biogen in Q2 2023 and has held it in 9 quarters since.
  • GTS Securities's Biogen position peaked at $4.14M in Q4 2023.
  • 1,048 funds tracked by Wall St. Rank held Biogen as of Q3 2026.

Based on GTS Securities's 13F filing for Q3 2026, filed 16 Nov 2026.